This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80: 2191–2198.
Schoch C, Haferlach T, Haase D, Fonatsch C, Loffler H, Schlegelberger B et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001; 112: 118–126.
Krauter J, Peter W, Pascheberg U, Heinze B, Bergmann L, Hoelzer D et al. Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. Br J Haematol 1998; 103: 72–78.
Slape C, Aplan PD . The role of NUP98 gene fusions in hematologic malignancy. Leuk Lymphoma 2004; 45: 1341–1350.
Huang N, vom BE, Garnier JM, Lerouge T, Vonesch JL, Lutz Y et al. Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J 1998; 17: 3398–3412.
Kurotaki N, Harada N, Yoshiura K, Sugano S, Niikawa N, Matsumoto N . Molecular characterization of NSD1, a human homologue of the mouse Nsd1 gene. Gene 2001; 279: 197–204.
Wang GG, Cai L, Pasillas MP, Kamps MP . NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007; 9: 804–812.
Hollink IH, Van den Heuvel-Eibrink MM, rentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011; 118: 3645–3656.
Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825–1832.
Chou WC, Chen CY, Hou HA, Lin LI, Tang JL, Yao M et al. Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Leukemia 2009; 23: 1303–1310.
Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia 2006; 20: 1295–1297.
Taketani T, Taki T, Nakamura T, Kobayashi Y, Ito E, Fukuda S et al. High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes. Leukemia 2010; 24: 1975–1977.
Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA . The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001; 20: 1897–1909.
King-Underwood L, Pritchard-Jones K . Wilms’ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961–2968.
Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372–4380.
Acknowledgements
We thank all clinicians for sending samples to our laboratory for diagnostic purposes, and for providing clinical information and follow-up data. In addition, we would like to thank all the co-workers at the MLL (Munich Leukemia Laboratory) for approaching together many aspects in the field of leukemia diagnostics and research. Especially the technical assistance of Nicole Schlenther, who performed NUP98–NSD1-specific qRT-PCR analyses, is greatly appreciated. In addition, we are grateful for the data management support performed by Tamara Alpermann.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
CH, WK, TH, and SS have equity ownership of MLL Munich Leukemia Laboratory GmbH. AF and TA are employed by MLL Munich Leukemia Laboratory GmbH.
Additional information
Supplementary information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Fasan, A., Haferlach, C., Alpermann, T. et al. A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98–NSD1 fusion gene. Leukemia 27, 245–248 (2013). https://doi.org/10.1038/leu.2012.230
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.230
This article is cited by
-
Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
Leukemia (2019)
-
NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis
Leukemia (2017)
-
Identification of MYC mutations in acute myeloid leukemias with NUP98–NSD1 translocations
Leukemia (2016)